Video

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Christian S. Hinrichs, MD, chief of Cancer Immunotherapy, and co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, program co-leader of the Cancer Metabolism and Growth Program at Rutgers Cancer Institute of New Jersey, professor of Medicine at the Rutgers Robert Wood Johnson Medical School, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Currently, the biggest unmet need in cellular therapy in epithelial cancer is, in turn, the largest unmet need in cancer overall, Hinrichs says. Many patients with epithelial cancer are diagnosed at an advanced stage and curative therapies are not available for patients with metastatic disease, Hinrichs adds. Although some patients can be cured, it is rare which makes this a significantly challenging disease to manage, Hinrichs says.

Research efforts are trying to develop better treatments, and especially trying to develop curative therapies for patients with metastatic epithelial cancers, Hinrichs concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP